Arlinda Lee
Stock Analyst at Canaccord Genuity
(1.60)
# 2,999
Out of 4,667 analysts
48
Total ratings
54.55%
Success rate
12.68%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Arlinda Lee
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| DCTH Delcath Systems | Maintains: Buy | $18 → $21 | $9.63 | +118.07% | 3 | Sep 7, 2023 | |
| XFOR X4 Pharmaceuticals | Maintains: Buy | $20 → $10 | $0.34 | +2,837.72% | 3 | Apr 5, 2022 | |
| NKTR Nektar Therapeutics | Maintains: Buy | $25 → $6 | $1.00 | +500.00% | 5 | Mar 16, 2022 | |
| RYTM Rhythm Pharmaceuticals | Maintains: Buy | $45 → $36 | $59.36 | -39.35% | 3 | Mar 7, 2022 | |
| CELC Celcuity | Initiates: Buy | $50 | $12.78 | +291.24% | 1 | Oct 8, 2021 | |
| CRSP CRISPR Therapeutics AG | Maintains: Buy | $151 → $160 | $47.26 | +238.55% | 3 | Aug 16, 2021 | |
| BCYC Bicycle Therapeutics | Maintains: Buy | $36 → $40 | $20.36 | +96.46% | 3 | Jul 15, 2021 | |
| RARE Ultragenyx Pharmaceutical | Maintains: Buy | $92 → $105 | $46.40 | +126.29% | 12 | Oct 29, 2020 | |
| HALO Halozyme Therapeutics | Maintains: Buy | $23 → $27 | $45.76 | -41.00% | 3 | May 19, 2020 | |
| BPMC Blueprint Medicines | Maintains: Buy | $115 → $100 | $94.81 | +5.47% | 5 | Apr 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $50 | $2.43 | +1,957.61% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $15 → $18 | $0.78 | +2,222.58% | 3 | Nov 5, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $24 | $0.31 | +7,768.85% | 2 | Aug 15, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $300 → $160 | $1.47 | +10,784.35% | 1 | Mar 29, 2018 |
Delcath Systems
Sep 7, 2023
Maintains: Buy
Price Target: $18 → $21
Current: $9.63
Upside: +118.07%
X4 Pharmaceuticals
Apr 5, 2022
Maintains: Buy
Price Target: $20 → $10
Current: $0.34
Upside: +2,837.72%
Nektar Therapeutics
Mar 16, 2022
Maintains: Buy
Price Target: $25 → $6
Current: $1.00
Upside: +500.00%
Rhythm Pharmaceuticals
Mar 7, 2022
Maintains: Buy
Price Target: $45 → $36
Current: $59.36
Upside: -39.35%
Celcuity
Oct 8, 2021
Initiates: Buy
Price Target: $50
Current: $12.78
Upside: +291.24%
CRISPR Therapeutics AG
Aug 16, 2021
Maintains: Buy
Price Target: $151 → $160
Current: $47.26
Upside: +238.55%
Bicycle Therapeutics
Jul 15, 2021
Maintains: Buy
Price Target: $36 → $40
Current: $20.36
Upside: +96.46%
Ultragenyx Pharmaceutical
Oct 29, 2020
Maintains: Buy
Price Target: $92 → $105
Current: $46.40
Upside: +126.29%
Halozyme Therapeutics
May 19, 2020
Maintains: Buy
Price Target: $23 → $27
Current: $45.76
Upside: -41.00%
Blueprint Medicines
Apr 30, 2020
Maintains: Buy
Price Target: $115 → $100
Current: $94.81
Upside: +5.47%
Feb 24, 2020
Initiates: Buy
Price Target: $50
Current: $2.43
Upside: +1,957.61%
Nov 5, 2019
Maintains: Buy
Price Target: $15 → $18
Current: $0.78
Upside: +2,222.58%
Aug 15, 2018
Maintains: Buy
Price Target: $22 → $24
Current: $0.31
Upside: +7,768.85%
Mar 29, 2018
Maintains: Buy
Price Target: $300 → $160
Current: $1.47
Upside: +10,784.35%